JP7767279B2 - 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用 - Google Patents

骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用

Info

Publication number
JP7767279B2
JP7767279B2 JP2022525704A JP2022525704A JP7767279B2 JP 7767279 B2 JP7767279 B2 JP 7767279B2 JP 2022525704 A JP2022525704 A JP 2022525704A JP 2022525704 A JP2022525704 A JP 2022525704A JP 7767279 B2 JP7767279 B2 JP 7767279B2
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
subject
administered
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022525704A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500326A5 (cg-RX-API-DMAC7.html
JP2023500326A (ja
Inventor
シャオリ ワン,
フェイ ファン,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Geron Corp
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of JP2023500326A publication Critical patent/JP2023500326A/ja
Publication of JP2023500326A5 publication Critical patent/JP2023500326A5/ja
Priority to JP2025009336A priority Critical patent/JP2025061603A/ja
Application granted granted Critical
Publication of JP7767279B2 publication Critical patent/JP7767279B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022525704A 2019-11-04 2020-11-03 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用 Active JP7767279B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009336A JP2025061603A (ja) 2019-11-04 2025-01-22 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962930251P 2019-11-04 2019-11-04
US62/930,251 2019-11-04
PCT/US2020/058718 WO2021091904A1 (en) 2019-11-04 2020-11-03 Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009336A Division JP2025061603A (ja) 2019-11-04 2025-01-22 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用

Publications (3)

Publication Number Publication Date
JP2023500326A JP2023500326A (ja) 2023-01-05
JP2023500326A5 JP2023500326A5 (cg-RX-API-DMAC7.html) 2023-11-14
JP7767279B2 true JP7767279B2 (ja) 2025-11-11

Family

ID=75848061

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022525704A Active JP7767279B2 (ja) 2019-11-04 2020-11-03 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用
JP2025009336A Pending JP2025061603A (ja) 2019-11-04 2025-01-22 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009336A Pending JP2025061603A (ja) 2019-11-04 2025-01-22 骨髄増殖性腫瘍の治療のためのヤヌスキナーゼ阻害剤およびテロメラーゼ阻害剤の使用

Country Status (11)

Country Link
US (2) US12391946B2 (cg-RX-API-DMAC7.html)
EP (1) EP4054594A4 (cg-RX-API-DMAC7.html)
JP (2) JP7767279B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220130669A (cg-RX-API-DMAC7.html)
CN (1) CN115666588A (cg-RX-API-DMAC7.html)
AU (1) AU2020380245A1 (cg-RX-API-DMAC7.html)
CA (1) CA3156376A1 (cg-RX-API-DMAC7.html)
IL (1) IL292596A (cg-RX-API-DMAC7.html)
MX (1) MX2022005354A (cg-RX-API-DMAC7.html)
TW (1) TW202133854A (cg-RX-API-DMAC7.html)
WO (1) WO2021091904A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法
EP4463151A4 (en) 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6162709B2 (ja) * 2011-11-01 2017-07-12 セルジーン コーポレイション シチジンアナログの経口製剤を使用して癌を治療する方法
KR102242077B1 (ko) * 2012-11-15 2021-04-20 인사이트 홀딩스 코포레이션 룩솔리티니브의 서방성 제형
PT3456333T (pt) 2012-12-07 2020-06-01 Geron Corp Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
US20150342982A1 (en) * 2012-12-07 2015-12-03 Geron Corporation Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Blood Advances,2018年,2(18),pp.2378-2388,DOI 10.1182/bloodadvances.2018022012.
Blood Advances,2018年,2(24),pp.3572-3580,DOI:10.1182/bloodadvances.2018019661.
Blood,2019年11月13日,134, Suppl.1,2963
Expert Opinion on Orphan Drugs,2016年,4(5),pp.521-529,DOI: 10.1517/21678707.2016.1171141
Expert opinion on orphan drugs,2019年09月24日,7(10),pp. 415-425

Also Published As

Publication number Publication date
JP2025061603A (ja) 2025-04-10
CN115666588A (zh) 2023-01-31
US12391946B2 (en) 2025-08-19
TW202133854A (zh) 2021-09-16
EP4054594A4 (en) 2023-12-13
JP2023500326A (ja) 2023-01-05
IL292596A (en) 2022-07-01
MX2022005354A (es) 2022-10-21
EP4054594A1 (en) 2022-09-14
AU2020380245A1 (en) 2022-05-19
CA3156376A1 (en) 2021-05-14
WO2021091904A1 (en) 2021-05-14
US20210269807A1 (en) 2021-09-02
US20260078379A1 (en) 2026-03-19
KR20220130669A (ko) 2022-09-27

Similar Documents

Publication Publication Date Title
US20220168333A1 (en) Combination Treatment for Hematological Cancers
JP7288098B2 (ja) 骨髄増殖性疾患および骨髄増殖性腫瘍を処置するためのテロメラーゼ阻害剤の使用
US20260078379A1 (en) Use of a Janus Kinase Inhibitor and a Telomerase Inhibitor for the Treatment of Myeloproliferative Neoplasms
US20150342982A1 (en) Use of Telomerase Inhibitors for the Treatment of Myeloproliferative Disorders and Myeloproliferative Neoplasms
HK40087531A (en) Use of a janus kinase inhibitor and a telomerase inhibitor for the treatment of myeloproliferative neoplasms
US20240091247A1 (en) Inhibitor for chronic myeloid leukemia stem cells
WO2026064898A1 (en) Combination therapies
JP2020176145A (ja) 血液癌の併用療法
HK40018627A (en) The telomerase inhibitor imetelstat for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
HK40002948B (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
HK40002948A (en) Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia
HK40009285B (en) Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome
HK40009285A (en) Use of the telomerase inhibitor imetelstat for the treatment of myelodysplastic syndrome
OA17327A (en) Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms.
HK1212226B (en) Use of the telomerase inhibitor imetelstat for the treatment of myelofibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250414

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250707

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251010

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251029

R150 Certificate of patent or registration of utility model

Ref document number: 7767279

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150